{
    "clinical_study": {
        "@rank": "28567", 
        "acronym": "REDUC", 
        "arm_group": [
            {
                "arm_group_label": "Part A", 
                "arm_group_type": "Other", 
                "description": "Part A, to confirm a safe/tolerable and efficacious dose of romidepsin in HIV patients in a small cohort (n=6)"
            }, 
            {
                "arm_group_label": "Part B", 
                "arm_group_type": "Other", 
                "description": "Part B, to evaluate the safety/tolerability of Vacc-4x + rhuGM-CSF as adjunctive therapy to romidepsin and to assess the impact on the latent HIV reservoir and the ability to control viral load during an Analytical Treatment Interruption (n=20)."
            }
        ], 
        "brief_summary": {
            "textblock": "The REDUC (\"Kick and Kill\") trial's objective is to address one of the core issues with the\n      treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs.\n      The reservoirs are unaffected by conventional HIV medication and invisible to the immune\n      system. HDACi have the potential to activate (\"Kick\") these latently infected cells. This\n      will make the HIV infected cells visible to the immune system; the immune response generate\n      by Vacc-4x will be able to attack and eliminate (\"Kill\") the infected cells."
        }, 
        "brief_title": "Safety and Efficacy of the Histone Deacetylase Inhibitor Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV\u20101 Reservoir", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic HIV-infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age >18 years\n\n          2. Currently receiving cART and having received cART for a minimum of 1 year\n\n          3. HIV-1 plasma RNA <50 copies/mL for at least 1 year (excluding viral load blips)\n\n          4. CD4 T cell count \u2265500 cells/mm3\n\n        Exclusion Criteria:\n\n          1. CD4 T cell count nadir <200 cells/mm3\n\n          2. Previous treatment with an HDACi (Histone deacetylase inhibitor) within the previous\n             6 months\n\n          3. Any evidence of an active AIDS-defining opportunistic infection, active HBV or HCV\n             co-infection, significant cardiac disease, malignancy, transplantation, insulin\n             dependent diabetes mellitus or other protocol defined excluded medical condition\n\n          4. Use of any protocol defined contraindicated medication or vaccination\n\n          5. Unacceptable values of the hematologic and clinical chemistry parameters as defined\n             in the protocol.\n\n          6. Males or females who are unwilling or unable to use protocol defined methods of\n             contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092116", 
            "org_study_id": "PBC01-001", 
            "secondary_id": "2013-004747-23"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A", 
                    "Part B"
                ], 
                "intervention_name": "Romidepsin (Istodax\u00ae)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B", 
                "intervention_name": "Vacc-4x", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Part B", 
                "intervention_name": "rhuGM-CSF (Leukine\u00ae)", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Romidepsin", 
                "Histone Deacetylase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "contact": {
                "email": "olesoega@rm.dk", 
                "last_name": "Ole Schmeltz S\u00f8gaard, MD", 
                "phone": "+45 78 45 28 42"
            }, 
            "facility": {
                "address": {
                    "city": "Aarhus N", 
                    "country": "Denmark", 
                    "zip": "8200"
                }, 
                "name": "Aarhus University Hospital, Skejby Sygehus"
            }, 
            "investigator": {
                "last_name": "Lars \u00d8stergaard, MD, PhD, DMSc, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation Using Romidepsin, on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART", 
        "overall_official": {
            "affiliation": "Aarhus University Hospital", 
            "last_name": "Lars J\u00f8rgen \u00d8stergaard, MD, PhD, DMSc, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Health and Medicines Authority", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety and tolerability evaluation as measured by adverse events (AE), adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR), serious unexpected adverse reactions (SUSAR)", 
                "measure": "Primary endpoint Part A", 
                "safety_issue": "Yes", 
                "time_frame": "Part A 12 weeks"
            }, 
            {
                "description": "1)\tSafety and tolerability evaluation as measured by adverse events (AE), adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR), serious unexpected adverse reactions (SUSAR)", 
                "measure": "Primary endpoint Part B", 
                "safety_issue": "Yes", 
                "time_frame": "Part B 41 weeks"
            }, 
            {
                "description": "2.Latent reservoir size measured in CD4+ T cells by: HIV-1 viral outgrowth assay (HIV-1 RNA per 106 in resting memory CD4+ T cells (RUPM))", 
                "measure": "Primary endpoint Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B Week 41"
            }, 
            {
                "description": "2.Latent reservoir size measured in CD4+ T cells by: Integrated HIV-1 DNA (copies per 106 CD4+ T cells)", 
                "measure": "Primary endpoint Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B Week 41"
            }, 
            {
                "description": "2.Latent reservoir size measured in CD4+ T cells by: Total HIV-1 DNA (copies per 106 CD4+ T cells)", 
                "measure": "Primary endpoint Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B Week 41"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092116"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "1) HIV transcription measured as cell associated unspliced HIV-1 RNA (copies per 106 CD4+ T cells)", 
                "measure": "Secondary endpoints Part A", 
                "safety_issue": "No", 
                "time_frame": "Part A 12 weeks"
            }, 
            {
                "description": "2) HIV transcription measured as plasma HIV RNA (by NAT screen and standard HIV RNA)", 
                "measure": "Secondary endpoints Part A", 
                "safety_issue": "No", 
                "time_frame": "Part A 12 weeks"
            }, 
            {
                "description": "3) Histone H3 acetylation in lymphocytes", 
                "measure": "Secondary endpoints Part A", 
                "safety_issue": "No", 
                "time_frame": "Part A 12 weeks"
            }, 
            {
                "description": "4) Size of the latent HIV-1 reservoir as measured in CD4+ T cells as measured by\nHIV-1 viral outgrowth assay (HIV-1 RNA per 106 in resting memory CD4+ T cells (RUPM))\nIntegrated HIV-1 DNA (copies per 106 CD4+ T cells)\nTotal HIV-1 DNA (copies per 106 CD4+ T cells)", 
                "measure": "Secondary endpoints Part A", 
                "safety_issue": "No", 
                "time_frame": "Part A 12 weeks"
            }, 
            {
                "description": "1) Time to re-initiation of cART", 
                "measure": "Secondary Endpoints Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B 41 weeks"
            }, 
            {
                "description": "2) Time to detectable viremia during cessation of cART", 
                "measure": "Secondary Endpoints Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B 41 weeks"
            }, 
            {
                "description": "3) HIV transcription measured as cell associated unspliced HIV-1 RNA (copies per 10\u2076 CD4+ T cells)", 
                "measure": "Secondary Endpoints Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B 41 weeks"
            }, 
            {
                "description": "4) HIV-specific T-cell responses as measured by ELISpot, proliferation and/or intracellular cytokine staining", 
                "measure": "Secondary Endpoints Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B 41 weeks"
            }, 
            {
                "description": "5) Plasma HIV-1 viral load", 
                "measure": "Secondary Endpoints Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B 41 weeks"
            }, 
            {
                "description": "6) Histone H3 acetylation as measured in lymphocytes", 
                "measure": "Secondary Endpoints Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B 41 weeks"
            }, 
            {
                "description": "7) T cell count and phenotype", 
                "measure": "Secondary Endpoints Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B 41 weeks"
            }, 
            {
                "description": "8) Antibody titer to Vacc-4x peptides and to p24 as measured by ELISA", 
                "measure": "Secondary Endpoints Part B", 
                "safety_issue": "No", 
                "time_frame": "Part B 41 weeks"
            }
        ], 
        "source": "Bionor Immuno AS", 
        "sponsors": {
            "collaborator": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bionor Immuno AS", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}